These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 11867754)
1. Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis. Liu S; Liu W; Jakubczak JL; Erexson GL; Tindall KR; Chan R; Muller WJ; Adhya S; Garges S; Merlino G Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3770-5. PubMed ID: 11867754 [TBL] [Abstract][Full Text] [Related]
2. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus. Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997 [TBL] [Abstract][Full Text] [Related]
3. Involvement of Notch1 in the development of mouse mammary tumors. Diévart A; Beaulieu N; Jolicoeur P Oncogene; 1999 Oct; 18(44):5973-81. PubMed ID: 10557086 [TBL] [Abstract][Full Text] [Related]
4. Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target. Jakubczak JL; Merlino G; French JE; Muller WJ; Paul B; Adhya S; Garges S Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9073-8. PubMed ID: 8799156 [TBL] [Abstract][Full Text] [Related]
5. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676 [TBL] [Abstract][Full Text] [Related]
6. Investigating DNA adduct-targeted mutagenicity of tamoxifen: preferential formation of tamoxifen-DNA adducts in the human p53 gene in SV40 immortalized hepatocytes but not endometrial carcinoma cells. Besaratinia A; Pfeifer GP Biochemistry; 2005 Jun; 44(23):8418-27. PubMed ID: 15938631 [TBL] [Abstract][Full Text] [Related]
7. A transgenic mouse model for mammary carcinogenesis. Li B; Murphy KL; Laucirica R; Kittrell F; Medina D; Rosen JM Oncogene; 1998 Feb; 16(8):997-1007. PubMed ID: 9519874 [TBL] [Abstract][Full Text] [Related]
9. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cadieux C; Kedinger V; Yao L; Vadnais C; Drossos M; Paquet M; Nepveu A Cancer Res; 2009 Sep; 69(18):7188-97. PubMed ID: 19738070 [TBL] [Abstract][Full Text] [Related]
10. Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation. Oh KB; Stanton MJ; West WW; Todd GL; Wagner KU Oncogene; 2007 Aug; 26(40):5950-9. PubMed ID: 17369844 [TBL] [Abstract][Full Text] [Related]
11. Co-opted integrin signaling in ErbB2-induced mammary tumor progression. Carraway KL; Sweeney C Cancer Cell; 2006 Aug; 10(2):93-5. PubMed ID: 16904607 [TBL] [Abstract][Full Text] [Related]
12. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418 [TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984 [TBL] [Abstract][Full Text] [Related]
14. Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model. Yoshidome K; Shibata MA; Maroulakou IG; Liu ML; Jorcyk CL; Gold LG; Welch VN; Green JE Int J Oncol; 1998 Feb; 12(2):449-53. PubMed ID: 9458374 [TBL] [Abstract][Full Text] [Related]
16. Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland. Smith AP; Henze M; Lee JA; Osborn KG; Keck JM; Tedesco D; Bortner DM; Rosenberg MP; Reed SI Oncogene; 2006 Nov; 25(55):7245-59. PubMed ID: 16751806 [TBL] [Abstract][Full Text] [Related]
17. Mutational signature of the proximate bladder carcinogen N-hydroxy-4-acetylaminobiphenyl: inconsistency with the p53 mutational spectrum in bladder cancer. Besaratinia A; Bates SE; Pfeifer GP Cancer Res; 2002 Aug; 62(15):4331-8. PubMed ID: 12154037 [TBL] [Abstract][Full Text] [Related]
18. Single nucleotide instability without microsatellite instability in rat mammary carcinomas. Watanabe N; Okochi E; Hirayama Y; Shimada Y; Yanagihara K; Yoshida MC; Takahashi S; Mochizuki M; Sugimura T; Nagao M; Ushijima T Cancer Res; 2001 Mar; 61(6):2632-40. PubMed ID: 11289141 [TBL] [Abstract][Full Text] [Related]
19. G-to-T transversions and small tandem base deletions are the hallmark of mutations induced by ultraviolet a radiation in mammalian cells. Besaratinia A; Synold TW; Xi B; Pfeifer GP Biochemistry; 2004 Jun; 43(25):8169-77. PubMed ID: 15209513 [TBL] [Abstract][Full Text] [Related]
20. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Weaver Z; Montagna C; Xu X; Howard T; Gadina M; Brodie SG; Deng CX; Ried T Oncogene; 2002 Aug; 21(33):5097-107. PubMed ID: 12140760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]